A recent study by the Indian Council of Medical Research reveals that Bharat Biotech's Covaxin is effective against the rampant Delta Plus variant of COVID-19. Covaxin was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology (NIV). Earlier, Bharat Biotech had said that Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

A recent study by the Indian Council of Medical Research reveals that Bharat Biotech's Covaxin is effective against the rampant Delta Plus variant of COVID-19. Covaxin was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology (NIV). Earlier, Bharat Biotech had said that Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.